Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseLong-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginasesClinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutAllergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.High-throughput asparaginase activity assay in serum of children with leukemiaThe low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.IV Administration of Erwinia-Derived Asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia: Single-Centre Case Series.Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes.The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
P2860
Q26738640-A74BF46A-0679-4F9F-9EB0-43EAB1D8C92AQ27026476-DCF4DB82-DF82-4E36-82F1-CC5192437661Q30371340-2A81968C-6646-4959-A1D9-8E817884A841Q33680270-3CB35173-A208-492C-B63C-24B73B1AC361Q34400424-67276CD3-1C9D-4A59-A792-CB4539024783Q35178966-4AC5CD06-7EB5-44DB-BAB0-4BC603FB7E2EQ35758669-F9848E2A-3A7C-4FD2-A174-29AE5F885ABDQ35921240-5F730DBD-0B2D-4F86-AB7D-1D3B1C7819EAQ36452241-A13F2CB7-2114-42C5-B8C0-4D98E90601D1Q36470511-56734EB3-FADF-426D-998A-7CFED4171AFEQ36649984-7492FFE1-0DB5-4D34-9658-B351E97EFBA7Q36678136-E66976A6-ED71-4DEF-BB3C-4D006F1F2EE3Q36697877-E6A00A41-3449-454C-A770-4EAF74D3354BQ36762608-853B52FF-7A1B-4D72-9FEC-7D9B591A9ADCQ37046992-DDD663AE-37A0-49D4-BF58-AEFBB44DBD28Q37063860-2429146F-5A9C-4F36-BF73-D103C088C910Q37078647-BFBA758D-C4AD-4C18-88C3-2554A6AED860Q38079075-3F1149DA-FEAD-4D07-8972-C774AF45014AQ38248280-A0372D80-E47B-4644-AEB9-8F4812547FE9Q38755617-869CE17F-DA81-4FFA-8FF7-BE8765EBCDB9Q41150769-CF57895D-322A-4E94-8EA8-FD406CD226C3Q42001967-9082CA79-91F3-49AA-8078-A02607BE03D4Q43031862-BCC21801-E9E4-49E7-B765-7F7EC8B82D94Q46125207-B74EF762-B1DA-4A5E-8118-50A7CC5F7A89Q49697799-97033B88-B72D-494C-9238-17F26396A55DQ49838778-0DD76227-D42D-48D1-AEC4-A76304F8EAA9
P2860
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Erwinia asparaginase after all ...... acute lymphoblastic leukemia.
@en
type
label
Erwinia asparaginase after all ...... acute lymphoblastic leukemia.
@en
prefLabel
Erwinia asparaginase after all ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P356
P1476
Erwinia asparaginase after all ...... acute lymphoblastic leukemia.
@en
P2093
Barbara L Asselin
Bruno Michon
Caroline Laverdière
Donna S Neuberg
Harvey J Cohen
Jeffrey G Supko
Kara M Kelly
Lewis B Silverman
Luis Clavell
Lynda M Vrooman
P2860
P304
P356
10.1002/PBC.22225
P577
2010-02-01T00:00:00Z